The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (56)
September 13, 2004
- Maurer's Healthcare Insight (55)
July 26, 2004
- Maurer's Healthcare Insight (54)
May 17, 2004
- Maurer's Healthcare Insight (53)
April 19, 2004
- Maurer's Healthcare Insight (52)
March 22, 2004
- Maurer's Healthcare Insight (51)
March 1, 2004
- Maurer's Healthcare Insight (50)
February 16, 2004
- Maurer's Healthcare Insight (49)
January 26, 2004
- Maurer's Healthcare Insight (48)
December 1, 2003
- Maurer's Healthcare Insight (47)
November 3, 2003
- Maurer's Healthcare Insight (46)
October 6, 2003
- Maurer's Healthcare Insight (45)
September 8, 2003
- Maurer's Healthcare Insight (44)
August 11, 2003
- Maurer's Healthcare Insight (43)
July 14, 2003
- Maurer's Healthcare Insight (42)
June 16, 2003
- Maurer's Healthcare Insight (41)
May 19, 2003
- Maurer's Healthcare Insight (40)
April 28, 2003
- Maurer's Healthcare Insight (39)
April 14, 2003
- Maurer's Healthcare Insight (Special)
March 24, 2003
- Maurer's Healthcare Insight (Special)
March 17, 2003
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…